Total Funding
57
47
Total FundingSeries A raised
Growth Score
-8 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
27933
Mosanna Therapeutics develops a nasal spray for treating obstructive sleep apnea.
- David Weber: President and CEOPast Role: Oculis, Executive Vice President
About the Company
Mosanna Therapeutics develops a nighttime nasal spray aimed at treating obstructive sleep apnea (OSA) by enhancing the body’s natural airway control. The company focuses on innovative pharmaceutical solutions to address the challenges associated with sleep-related disorders. By leveraging cutting-edge research, Mosanna Therapeutics aims to improve
patient outcomes for those affected by OSA. The company’s commitment to advancing clinical initiatives is evident in its approach to developing effective treatments. Through its novel product, Mosanna Therapeutics seeks to provide a viable option for individuals struggling with this condition, contributing to the broader field of sleep medicine.
